FDA-approved indication (August 26, 2026)
RASONQUE (daraxonrasib) is indicated for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multi-agent systemic therapy.
Notably, the indication is not restricted by RAS mutation status. In RASolute 302, both the RAS G12-mutant population and the overall population derived consistent survival benefit, and since more than 90% of pancreatic adenocarcinomas carry a KRAS mutation, the indication covers the great majority of previously treated patients with metastatic disease. Whether molecular testing is needed before treatment should be guided by the current prescribing information and the treating physician.
Recommended dose and administration
| Recommended dose | 300 mg orally once daily |
|---|---|
| Duration | Until disease progression or unacceptable toxicity |
| Formulation | Oral tablets |
| Dose modification | Interrupt, reduce or permanently discontinue according to the severity of adverse reactions; see the prescribing information for details |
For missed doses, administration with or without food, and drug interactions (e.g. strong CYP3A inhibitors/inducers), refer to the FDA-approved prescribing information (USPI).
Indications in development
| Indication | Study | Phase | Status |
|---|---|---|---|
| First-line metastatic pancreatic adenocarcinoma (monotherapy and with chemotherapy) | RASolute 303 | Phase 3 | Recruiting |
| Adjuvant therapy after resection of pancreatic adenocarcinoma | RASolute 304 | Phase 3 | Recruiting |
| Previously treated RAS-mutant non-small cell lung cancer | RASolve 301 | Phase 3 | Recruiting |
| RAS-mutant solid tumors (including colorectal cancer) | RMC-6236-001 and combination studies | Phase 1/2 | Ongoing |
Regional availability
- United States: approved by the FDA on August 26, 2026. Before approval, the FDA had authorised an Expanded Access Protocol allowing eligible patients to receive the drug.
- European Union, Japan and others: no approval had been publicly announced as of this site's last update; follow Revolution Medicines' official communications for regulatory filing progress.
- China: as of this site's last update, daraxonrasib had not been approved in mainland China. Clinical trial opportunities can be checked on ClinicalTrials.gov or the Chinese drug trial registry (ChinaDrugTrials).
Important: this page is not treatment advice. All treatment decisions should be made by a qualified oncologist based on the individual patient's situation.
Last updated: September 5, 2026
Content reviewed: September 5, 2026